Pherecydes Pharma SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pherecydes Pharma SA
BioNTech's $270m Series A round was the biggest start-up financing in January, but sizeable rounds also were raised by Centrexion ($67m), Eureka ($60m) and Pandion ($58m).
Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.
Gilead licensed rights to four preclinical antibodies from MacroGenics. Stryker bought Chinese device company Trauson for $751 million. Biopharma companies raised double the amount from December, bringing in $2.8 billion, while device funding dropped to $269 million.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.
- In Vitro Diagnostics
- Nanotechnology, Chips, etc.